NXT

NXT is a non-specific name that primarily refers to several distinct drug candidates or brand suffixes in the pharmaceutical and biotechnology sectors. Most notably, it is frequently used as a shorthand for **NXT007**, a bispecific monoclonal antibody developed by Chugai Pharmaceutical that acts as a Factor VIII-mimetic for the treatment of Hemophilia A. Another significant candidate is **NXT-629**, a small molecule diacylglycerol kinase alpha (DGKα) inhibitor developed by Curon Biopharmaceutical for the treatment of solid tumors. Additionally, 'NXT' is a common suffix used in brand names (e.g., Telma NXT, Montair NXT) by various pharmaceutical companies, particularly in India, to denote next-generation formulations or combination products. Because the name 'NXT' does not refer to a single unique chemical entity, it is classified as non-specific.